Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia.

@article{Thadhani2011PilotSO,
  title={Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia.},
  author={Ravi I. Thadhani and Tuelay Kisner and Henning Hagmann and Verena Bossung and Stefanie Noack and Wiebke Schaarschmidt and Alexander Jank and Angela Kribs and Oliver A Cornely and Claudia Kreyssig and Linda C Hemphill and Alan C. Rigby and Santosh A. Khedkar and Tom H. Lindner and Peter K Mallmann and Holger Stepan and Siddharth Karumanchi and Thomas Benzing},
  journal={Circulation},
  year={2011},
  volume={124 8},
  pages={940-50}
}
BACKGROUND Targeted therapies to stabilize the clinical manifestations and prolong pregnancy in preeclampsia do not exist. Soluble fms-like tyrosine kinase 1 (sFlt-1), an alternatively spliced variant of the vascular endothelial growth factor receptor 1, induces a preeclampsia-like phenotype in experimental models and circulates at elevated levels in human preeclampsia. Removing sFlt-1 may benefit women with very preterm (<32 weeks) preeclampsia. METHODS AND RESULTS We first show that… CONTINUE READING